Eli Lilly and Company, Novo Nordisk A/S, AbbVie, Thermo Fisher Scientific, and Pfizer are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are equity shares of publicly traded companies that research, develop, manufacture, and market prescription drugs, vaccines, and related therapies. Investors in these stocks gain exposure to the pharmaceutical industry’s growth potential, which is driven by factors such as clinical trial results, regulatory approvals, patent lifecycles, and healthcare demand. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
LLY traded up $21.40 during trading on Friday, hitting $761.47. 4,857,388 shares of the company's stock were exchanged, compared to its average volume of 3,285,034. The stock has a 50 day moving average price of $775.51 and a 200 day moving average price of $799.86. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18. The firm has a market cap of $721.67 billion, a P/E ratio of 61.96, a price-to-earnings-growth ratio of 1.05 and a beta of 0.44.
Read Our Latest Research Report on LLY
Novo Nordisk A/S (NVO)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
Shares of NYSE:NVO traded up $1.16 on Friday, reaching $48.23. 34,710,384 shares of the company's stock were exchanged, compared to its average volume of 17,615,270. The business's 50-day moving average is $69.26 and its two-hundred day moving average is $72.73. The firm has a market capitalization of $215.35 billion, a price-to-earnings ratio of 14.27, a PEG ratio of 1.41 and a beta of 0.63. The company has a quick ratio of 0.56, a current ratio of 0.74 and a debt-to-equity ratio of 0.70. Novo Nordisk A/S has a fifty-two week low of $46.90 and a fifty-two week high of $139.74.
Read Our Latest Research Report on NVO
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Shares of NYSE:ABBV traded up $6.15 during trading hours on Friday, hitting $195.17. 8,081,230 shares of the company's stock traded hands, compared to its average volume of 5,440,562. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.64 and a current ratio of 0.76. AbbVie has a 52 week low of $163.81 and a 52 week high of $218.66. The company has a market cap of $344.75 billion, a price-to-earnings ratio of 92.94, a price-to-earnings-growth ratio of 1.25 and a beta of 0.50. The company's fifty day simple moving average is $188.33 and its two-hundred day simple moving average is $190.17.
Read Our Latest Research Report on ABBV
Thermo Fisher Scientific (TMO)
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
NYSE:TMO traded down $4.94 during mid-day trading on Friday, reaching $462.74. The stock had a trading volume of 2,756,840 shares, compared to its average volume of 3,223,400. Thermo Fisher Scientific has a fifty-two week low of $385.46 and a fifty-two week high of $627.88. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The business's 50 day moving average is $420.88 and its 200 day moving average is $467.66. The stock has a market cap of $174.68 billion, a P/E ratio of 26.76, a PEG ratio of 2.50 and a beta of 0.77.
Read Our Latest Research Report on TMO
Pfizer (PFE)
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
PFE stock traded up $0.20 during midday trading on Friday, hitting $23.49. The stock had a trading volume of 51,287,529 shares, compared to its average volume of 38,018,180. The firm has a market capitalization of $133.55 billion, a price-to-earnings ratio of 17.02, a P/E/G ratio of 0.84 and a beta of 0.52. The stock has a 50-day simple moving average of $24.36 and a 200 day simple moving average of $24.58. Pfizer has a 52 week low of $20.92 and a 52 week high of $31.32. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64.
Read Our Latest Research Report on PFE
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
